Jennifer Champoux
Geschäftsführer bei MONTE ROSA THERAPEUTICS, INC.
Vermögen: 809 999 $ am 31.05.2024
Profil
Jennifer Champoux currently works at Monte Rosa Therapeutics, Inc., as Chief Operating Officer from 2024.
Ms. Champoux also formerly worked at H3 Biomedicine, Inc., as Executive Director-Operations.
Ms. Champoux received her graduate degree from Indiana University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DIGITAL TURBINE, INC.
0,42% | 03.06.2024 | 428 571 ( 0,42% ) | 809 999 $ | 31.05.2024 |
| 03.06.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Jennifer Champoux
| Unternehmen | Position | Beginn |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Geschäftsführer | 01.03.2021 |
Ehemalige bekannte Positionen von Jennifer Champoux
| Unternehmen | Position | Ende |
|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - |
Ausbildung von Jennifer Champoux
| Indiana University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
